Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 135 | 47% |
| 2020 | 3 | 246 | 50% |
| 2021 | 6 | 284 | 53% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Ohio; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 114 | 4,105−5.1%/yr | −5.1%/yr | 3.61.2× | 8% | 4,010 in 2030−0.4%/yr |
| Lumbar fusion |
SI joint fusion in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Indiana
| 2024 |
| 367 |
| 60% |
| 2025 est. | ≈ 390 | – |
| 2026 est. | ≈ 430 | – |
| 2022 | 7 | 284 | 56% |
| 2023 | 5 | 331 | 58% |
| 2024 | 7 | 367 | 60% |
| 2025 from claims | – | 390 316–458 | 61% |
| 2026 forecast | – | 434 340–545 | 61% |
| 2027 forecast | – | 472 350–623 | 61% |
| 2028 forecast | – | 513 363–708 | 61% |
| 2029 forecast | – | 558 379–800 | 62% |
| 2030 forecast | – | 607 397–900 | 62% |
In 2025, 48% inpatient hospital, 40% hospital outpatient, 11% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +21%/yr |
| 0.3 |
| 41% |
| 350 in 2030+12%/yr |
| Missouri | 3 | 175−4%/yr | −4%/yr | 0.3 | 40% | 760 in 2030+28%/yr |
| Illinois | 2 | 171+8.4%/yr | +8.4%/yr | 0.1 | 0% | 380 in 2030+14%/yr |
| Kansas | 5 | 149+26%/yr | +26%/yr | 0.3 | 50% | 80 in 2030−9.1%/yr |
| Wisconsin | 3 | 135+14%/yr | +14%/yr | 0.2 | 100% | 140 in 2030+0.1%/yr |
| 90 |
| 3,677−2.1%/yr |
| −2.1%/yr |
| 3.21.2× |
| 1% |
| 4,120 in 2030+1.9%/yr |
| Cervical fusion & disc arthroplasty | 25 | 1,738−4.6%/yr | −4.6%/yr | 1.51.1× | 5% | 1,920 in 2030+1.7%/yr |
| Kyphoplasty & vertebroplasty | 15 | 1,537−7.3%/yr | −7.3%/yr | 1.41.0× | 1% | 1,360 in 2030−2.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
SI-BONE leads with 89% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 7 companies reported engagement with Ohio’s surgeons worth $60K in consulting, speaking, meals and travel tied to these products, about $8,546 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.